Multiplex PCR for Detection of a Successful Pathogen; Acinetobacter baumanni as a Real Threat in Intensive Care Unit of a University Hospital

Authors
E. Kalantar 1
M. Madani 2
A. Hatami 2
M. H. Dehghan 3
M. Ebadi 1
M. Nazari 2
S. Saifei 2
S. M. Amin Marashi 1
1 Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
2 Diagnostic Laboratory, Shahid Rajaei Hospital, Alborz University of Medical Sciences, Karaj, Iran.
3 Department of Biochemistry, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Abstract
Multidrug resistance in Acinetobacter baumannii is a growing public health concern all over the world. In the current study, the isolation and antimicrobial resistance pattern and detection of blaOXA-51 and lpxC genes by multiplex PCR method was performed.
All the isolates demonstrated high levels of resistance rates to amikacin, ciprofloxacin, meropenem, imipenem, ceftriaxone, gentamicin, and colistin. Screening of two resistance genes by multiplex PCR showed that all the isolates contained blaOXA-51 and lpxC genes. As we previously reported, nosocomial infections caused by A. baumannii isolates are a major cause of morbidity and mortality in our hospital.

Keywords

1.         Tena D, Martƒá nez NM,  Oteo J, Saáez D, Vinde A,  Azanãedo ML, et al. Outbreak of multiresistant OXA-24- and OXA-51-Producing Acinetobacter baumannii in an internal medicine ward. Jpn J Infect Dis. 2013; 66(4): 323-326.
2.         Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(10): 3471–3484.
3.         Montealegre MC, Maya JJ, Correa A, Espinal P, Mojica MF, Ruiz SJ, et al. First identification of OXA-72 carbapenemase from Acinetobacter pittii in Colombia. Antimicrob Agents Chemother. 2012; 56(7): 3996–3998.
4.         Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015; 60(9): 1295-303.
5.         Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. J Res Med Sci. 2014; 19(Suppl 1): S67–70.
6.         Farshadzadeh Z, Hashemi FB, Rahimi S, Pourakbari B, Esmaeili D, Haghighi MA, et al. Wide distribution of carbapenem resistant Acinetobacter baumannii in burns patients in Iran. Front Microbiol. 2015; 6: 1146.
7.         Kalantar E, Hatami A, Rahimi F, Saedi S, Heidari A, Fallah P, et al. Acinetobacter baumannii infection should be considered as the most troublesome pathogens for health care institutions in Karaj.  Avicenna J Clin Microb Infect. 2015; 6(2): 79-86.
8.         Wayne P: Clinical and Laboratory Standards Institute; 2011. CLSI. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement. CLSI document M100-S21.
9.         Dieffenbach CW, Lowe TM, Dveksler GS. General concepts for PCR primer design. Genome Res. 1993: 3(3): S30-7.
10.       Bakour S, Olaitan AO, Ammari H, Touati A, Saoudi S, Saoudi K, et al. Emergence of colistin- and carbapenem-resistant Acinetobacter baumannii ST2 clinical isolate in Algeria: first case report. Microb Drug Resist. 2015; 21(3): 279-85.
11.       Werneck JS, Pica˜o RC, Carvalhaes CG, Cardoso JP, Gales AC. OXA-72-producing Acinetobacterbaumannii in Brazil: a case report. J Antimicrob Chemother. 2011; 66(2): 452-454.
Infection Epidemiology and Microbiology
Volume 3, Issue 1 - Serial Number 6
January 2017
Pages 23-24